1. 1130OResponses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018) Authors: Tannir, N M; Naing, A; Papadopoulos, K P; Wong, D J; Korn, W M; Aljumaily, R; Autio, K A; Pant, S; Bauer, T M; Drakaki, A; Daver, N; Hung, A; Oft, M; Leveque, J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗